Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.55 |
| ▸ | JAK3 | P52333 | 4/20 | 0.55 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.50 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11395576 | 0.85 | JAK2 (0.55) | JAK2JAK3TRPM8SMN1; SMN2ALDH1A1 | |
| SCHEMBL11396911 | 0.84 | MEN1 (0.53) | JAK2JAK3SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL1776614 | 0.84 | KDM4E (0.51) | TRPM8SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL11396935 | 0.84 | ALDH1A1 (0.56) | JAK2JAK3SMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL11400381 | 0.82 | TLR8 (0.47) | POLBTDP1ALDH1A1LMNAMAPT | |
| SCHEMBL5772148 | 0.82 | ALDH1A1 (0.53) | JAK2JAK3SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL11400231 | 0.81 | MAPT (0.55) | SMN1; SMN2TDP1ALDH1A1MAPTMEN1 | |
| SCHEMBL5773232 | 0.81 | TEAD2 (0.46) | JAK2JAK3SMN1; SMN2POLBALDH1A1 | |
| SCHEMBL5771314 | 0.81 | TEAD2 (0.48) | JAK2JAK3SMN1; SMN2POLBALDH1A1 | |
| SCHEMBL5769963 | 0.81 | MEN1 (0.41) | JAK2JAK3SMN1; SMN2POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
| WO-2018064119-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. (US) | 2018-04-05 | — | — | WO | disclosed |
| US-7538132-B2 | Isoxazolo derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20070066668-A1 | Isoxazolo derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | JAK2 4186/4885JAK3 4766/4885TRPM8 1301/4885 |
| US-10894776-B2 | — | CAPNS1, CAPN9, CAPN2 | JAK2 3719/4885JAK3 4609/4885TRPM8 1267/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | JAK2 4186/4885JAK3 4766/4885TRPM8 1301/4885 |
| US-20070066668-A1 | Isoxazolo derivatives | GABRA5, GABRA4, GABRA1 | JAK2 2809/4885JAK3 3680/4885TRPM8 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.